Bridgend, UK – 18 September 2025: A new book titled “Transforming the Pharmaceutical Supply Chain” by Hedley Rees, published in September 2025, delves into deep-rooted issues within the pharmaceutical supply chain and publicly calls for major reform of the traditional practices of large pharmaceutical companies.
The book investigates long-standing problems like supply chain fragility, market concentration, and lack of transparency, highlighting how these factors contribute to persistent drug shortages, increased costs, and barriers to access.
In summary:
-
The book systematically exposes the vulnerabilities embedded in the current pharmaceutical supply models dominated by “Big Pharma,” addressing manufacturing, regulatory, and commercial practices that increase system risk and reduce patient access.
-
It argues that industry practices focused on short-term profitability and minimal transparency have made the supply chain brittle, especially in the face of global health crises or complex regulatory environments.
-
Rees proposes actionable reforms for industry and policymakers, including incentivizing domestic production, modernizing supply chain technology (e.g., AI, data integration), and enacting regulatory and purchasing oversight.
-
The release aligns with the growing momentum in 2025 for an industry-wide reckoning—echoed by recent policy discussions, academic publications, and sector forums—regarding the need for resilient, transparent, and equitable pharmaceutical supply systems.
The book is expected to catalyze further debate and policy activity around pharmaceutical supply chain reform, directly challenging the status quo and calling on both governments and industry leaders to take urgent, systemic action.
The book is available now, in the United States, from Wiley.com:
The Wiley launch in other markets, on Amazon, and in bookshops, will be staggered up to the end of this year.
Hedley Rees, author and Managing Director at PharmaFlow Ltd, commented:
‘When Wiley approached me to write this book at the height of the COVID pandemic, I was thrilled to accept the challenge. Two years on, it is immensely satisfying to see the project come to fruition. I am especially grateful for the opportunity to collaborate with 11 expert witnesses from across the pharmaceutical supply chain and broader industry disciplines, whose insights have given added depth and credibility to the principles and practices explored in the book.’
ENDS